Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 103

1.

Beyond dopamine: glutamate as a target for future antipsychotics.

Sendt KV, Giaroli G, Tracy DK.

ISRN Pharmacol. 2012;2012:427267. doi: 10.5402/2012/427267. Epub 2012 Jul 5.

PMID:
22830044
[PubMed]
Free PMC Article
2.

Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia.

Heresco-Levy U.

Expert Opin Emerg Drugs. 2005 Nov;10(4):827-44. Review.

PMID:
16262565
[PubMed - indexed for MEDLINE]
3.

Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis.

de Bartolomeis A, Fiore G, Iasevoli F.

Curr Pharm Des. 2005;11(27):3561-94. Review.

PMID:
16248808
[PubMed - indexed for MEDLINE]
4.

Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.

Chavez-Noriega LE, Schaffhauser H, Campbell UC.

Curr Drug Targets CNS Neurol Disord. 2002 Jun;1(3):261-81. Review.

PMID:
12769619
[PubMed - indexed for MEDLINE]
5.

Glutamate receptor abnormalities in schizophrenia: implications for innovative treatments.

Rubio MD, Drummond JB, Meador-Woodruff JH.

Biomol Ther (Seoul). 2012 Jan;20(1):1-18. doi: 10.4062/biomolther.2012.20.1.001. Review.

PMID:
24116269
[PubMed]
Free PMC Article
6.

Glutamatergic neurotransmission modulation and the mechanisms of antipsychotic atypicality.

Heresco-Levy U.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1113-23. Review.

PMID:
14642971
[PubMed - indexed for MEDLINE]
7.

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia.

Fell MJ, McKinzie DL, Monn JA, Svensson KA.

Neuropharmacology. 2012 Mar;62(3):1473-83. doi: 10.1016/j.neuropharm.2011.06.007. Epub 2011 Jun 21. Review.

PMID:
21704048
[PubMed - indexed for MEDLINE]
8.

[Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].

Mechri A, Saoud M, Khiari G, d'Amato T, Dalery J, Gaha L.

Encephale. 2001 Jan-Feb;27(1):53-9. Review. French.

PMID:
11294039
[PubMed - indexed for MEDLINE]
9.

Novel therapies for schizophrenia: understanding the glutamatergic synapse and potential targets for altering N-methyl-D-aspartate neurotransmission.

Hui C, Wardwell B, Tsai GE.

Recent Pat CNS Drug Discov. 2009 Nov;4(3):220-38. Review.

PMID:
19891601
[PubMed - indexed for MEDLINE]
10.

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia.

Goff DC, Coyle JT.

Am J Psychiatry. 2001 Sep;158(9):1367-77. Review.

PMID:
11532718
[PubMed - indexed for MEDLINE]
11.

Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?

Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H.

Mol Pharmacol. 2010 Mar;77(3):317-26. doi: 10.1124/mol.109.059865. Epub 2009 Nov 23. Review. Erratum in: Mol Pharmacol. 2010 May;77(5):884.

PMID:
19933774
[PubMed - indexed for MEDLINE]
Free Article
12.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
[PubMed - indexed for MEDLINE]
13.

Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia.

de Bartolomeis A, Sarappa C, Magara S, Iasevoli F.

Eur J Pharmacol. 2012 May 5;682(1-3):1-11. doi: 10.1016/j.ejphar.2012.02.033. Epub 2012 Feb 24. Review.

PMID:
22387855
[PubMed - indexed for MEDLINE]
14.

Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Javitt DC.

Int Rev Neurobiol. 2007;78:69-108. Review.

PMID:
17349858
[PubMed - indexed for MEDLINE]
15.

Glutamate and schizophrenia: beyond the dopamine hypothesis.

Coyle JT.

Cell Mol Neurobiol. 2006 Jul-Aug;26(4-6):365-84. Epub 2006 Jun 14. Review.

PMID:
16773445
[PubMed - indexed for MEDLINE]
16.

Role of glutamate in schizophrenia: integrating excitatory avenues of research.

Sodhi M, Wood KH, Meador-Woodruff J.

Expert Rev Neurother. 2008 Sep;8(9):1389-406. doi: 10.1586/14737175.8.9.1389. Review.

PMID:
18759551
[PubMed - indexed for MEDLINE]
17.

Glutamate signaling in the pathophysiology and therapy of schizophrenia.

Lin CH, Lane HY, Tsai GE.

Pharmacol Biochem Behav. 2012 Feb;100(4):665-77. doi: 10.1016/j.pbb.2011.03.023. Epub 2011 Apr 1. Review.

PMID:
21463651
[PubMed - indexed for MEDLINE]
18.

Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development.

Müller N.

Expert Opin Ther Targets. 2008 Dec;12(12):1497-507. doi: 10.1517/14728220802507852 . Review.

PMID:
19007319
[PubMed - indexed for MEDLINE]
19.

How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?

Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U.

Neurochem Int. 2007 Jan;50(2):291-301. Epub 2006 Nov 7. Review.

PMID:
17084946
[PubMed - indexed for MEDLINE]
20.

[Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].

Pannese R, Minichino A, Pignatelli M, Delle Chiaie R, Biondi M, Nicoletti F.

Riv Psichiatr. 2012 Mar-Apr;47(2):149-69. doi: 10.1708/1069.11719. Review. Italian.

PMID:
22622251
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk